Can pre-treatment PSA reliably serve as a predictor of clinical failure and prostate cancer related death?

被引：0
|
作者：
Mayer, R [1 ]
Quehenberger, F [1 ]
Feigl, GC [1 ]
Pummer, K [1 ]
Langsenlehner, U [1 ]
Hackl, A [1 ]
机构：
[1] Graz Univ, Sch Med, Graz, Austria
来源：
INTERNATIONAL JOURNAL OF CANCER | 2002年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：369 / 369
页数：1
相关论文
共 50 条
  • [31] A comparative analysis of prostate cancer pre-treatment characteristics stratified by age
    Shah, Navin
    Ioffe, Vladimir
    Kapur, Anish
    [J]. CANADIAN JOURNAL OF UROLOGY, 2014, 21 (02) : 7213 - 7216
  • [32] Pre-treatment staging of prostate cancer: recent advances and future prospects
    Kirby, RS
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 1997, 1 (01) : 2 - 10
  • [33] Prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance
    van de Ven, Anne L.
    Tangutoori, Shifalika
    Baldwin, Paige
    Qiao, Ju
    Gharagouzloo, Codi
    Seitzer, Nina
    Clohessy, John
    Korideck, Houari
    Makrigiorgos, G. Mike
    Cormack, Robert
    Pandolfi, Pier Paolo
    Sridhar, Srinivas
    [J]. CANCER RESEARCH, 2017, 77
  • [34] Can Pre-treatment Quantitative Multi- parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer?
    Chatterjee, Aritrick
    Turchan, William Tyler
    Fan, Xiaobing
    Griffin, Alexander
    Yousuf, Ambereen
    Karczmar, Gregory S.
    Liauw, Stanley L.
    Oto, Aytekin
    [J]. ACADEMIC RADIOLOGY, 2022, 29 (07) : 977 - 985
  • [35] PRE-TREATMENT PSA VELOCITY IS ASSOCIATED WITH DEVELOPMENT OF DISTANT METASTASES AND PROSTATE CANCER MORTALITY IN MEN TREATED WITH RADIOTHERAPY AND ANDROGEN DEPRIVATION THERAPY
    Palma, D.
    Tyldesley, S.
    Pickles, T.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S18 - S18
  • [36] AFRICAN-AMERICAN RACE IS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER SPECIFIC DEATH AFTER PSA RECURRENCE
    Caso, Jorge
    Tang, Ping
    Tsivian, Matvey
    Mouraviev, Vladimir
    Polascik, Thomas
    Moul, Judd
    [J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E756 - E756
  • [37] Clinical experience with EPID dosimetry for prostate IMRT pre-treatment dose verification
    McDermott, L. N.
    Wendling, M.
    van Asselen, B.
    Stroom, J.
    Sonke, J. -J.
    van Herk, M.
    Mijnheer, B. J.
    [J]. MEDICAL PHYSICS, 2006, 33 (10) : 3921 - 3930
  • [38] Can PSA nadir predict prognosis in men receiving hormonal therapy for prostate cancer after primary treatment failure?
    Neil Fleshner
    [J]. Nature Clinical Practice Urology, 2006, 3 : 252 - 253
  • [39] Can PSA nadir predict prognosis in men receiving hormonal therapy for prostate cancer after primary treatment failure?
    Fleshner, N.
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (05): : 252 - 253
  • [40] PREDICTION OF FUTURE CASTRATION RESISTANT PROSTATE CANCER BY PRE-TREATMENT PROSTATE TISSUE ANDROGEN CONTENT
    Shibata, Yasuhiro
    Arai, Seiji
    Suzuki, Kazuhiro
    Honma, Seijiro
    Miyoshi, Yasuhide
    Kubota, Yoshinobu
    Tsukamoto, Taiji
    Ichikawa, Tomohiko
    Namiki, Mikio
    Sugimura, Yoshiki
    Okuyama, Akihiko
    Kanetake, Hiroshi
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E918 - E919
12345